The results showed that Apt-Td also demonstrated significantly higher binding to MUC1-positive cells versus MUC1-negative control cells (Figure 3B), indicating that Apt-Td retained the capacity to preferentially bind with the MUC1-positive cancer cells and thus may serve as a potential MUC1-targeting drug carrier. Here, MUC1 is linked to cancer.